IFN-α

Phase 2Small molecule

PPeking University People's Hospital

IFN-α is one of 34 small molecule programs targeting Myeloid Malignancy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloid MalignancyRecruiting

PreventionNot yet recruiting

Myeloid MalignancyPhase 2

Recruiting

PreventionPhase 2

Not yet recruiting

Competition

Competitive Landscape

38 competitors in Prevention

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

8 2

Prograf

VVeloxis Pharmaceuticals

Phase 3

4 3

Orencia

Bristol-Myers Squibb

Phase 2

2 4

Ilaris

Novartis

Phase 2

1 5

Cytoxan

BBaxter Healthcare Corporation

Phase 2

6 6

BCG Vaccine

GGynecologic Oncology Group

Phase 3

1 7

Epsom Salt

FFresenius Kabi USA, LLC

Phase 2

1 8

Didronel

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 9

CPX-351

Jazz Pharmaceuticals

Phase 2

1 10

CO2

CCapnia, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Prevention

NCT07449286

Clinical

Trials by Indication[1]

Glioma1 trial

A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas

Unknown status·SSun Yat-sen University·Phase 3·NCT01765088·300 enrolled

Renal Cell Carcinoma1 trial

Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

Terminated·—·Phase 2·NCT00913913·8 enrolled

Lymphoma1 trial

Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma

Completed·TThe Cleveland Clinic·Phase 1·NCT00276536·35 enrolled

Prevention1 trial

IFN-α in Relapse Prevention.

Not yet recruiting·PPeking University People's Hospital·Phase 2·NCT07449286·100 enrolled

Myeloid Malignancy1 trial

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

Recruiting·PPeking University People's Hospital·Phase 2·NCT06130579·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for IFN-α. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IFN-α compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IFN-α. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeking University People's Hospital

IFN-α

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Glioma1 trial

Renal Cell Carcinoma1 trial

Lymphoma1 trial

Prevention1 trial

Myeloid Malignancy1 trial

References

Drug Info

Quick Facts

Related News